Lupin receives final approval for generic generic Drospirenone, Ethinyl Estradiol, Levomefolate Calcium Tablets and Levomefolate Calcium Tablets
Lupin has received final approval for its Hydroxychloroquine Sulfate Tablets USP, 200 mg from the United States Food and Drug Administration (FDA) to market a generic version of Concordia Pharmaceuticals, Inc.'s Plaquenil Tablets, 200 mg.
Lupin's Hydroxychloroquine Sulfate Tablets USP, 200 mg is the generic version of Concordia Pharmaceuticals, Inc.'s Plaquenil Tablets, 200 mg.
It is indicated for: - the treatment of uncomplicated malaria due to P. falciparum, P. malariae, P. ovale, and P. vivax
- the prophylaxis of malaria in geographic areas where chloroquine resistance is not reported
- the treatment of acute and chronic rheumatoid arthritis in adults
Hydroxychloroquine Sulfate Tablets USP, 200 mg had annual sales of approximately USD 215.3 million in the US (IQVIA MAT April 2018).
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)